ELITE PHARMACEUTICALS INC /NV/ 4
4 · ELITE PHARMACEUTICALS INC /NV/ · Filed May 3, 2017
Insider Transaction Report
Form 4
Hakim Nasrat A
DirectorPresident & CEO
Transactions
- Other
Warrants
2017-04-28+79,008,661→ 79,008,661 totalExercise: $0.15Exp: 2027-04-28→ Common Stock (79,008,661 underlying) - Other
Series J Convertible Preferred Shares
2017-04-28$1000000.00/sh+24.034$24,034,400→ 24.034 totalExercise: $1000000.00→ Common Stock (158,017,321 underlying) - Other
Common Stock
2017-04-28−158,017,321→ 9,097,561 total
Holdings
- 2,700,000(indirect: By IRA)
Common Stock
Footnotes (4)
- [F1]The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company.
- [F2]The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock.
- [F3]The date that Shareholder Approval is obtained for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock and exercise of the warrants.
- [F4]None.